Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.33 |
| ▸ | HTR2A | P28223 | 7/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 8/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862934 | 0.94 | HTR2C (0.31) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30803937 | 0.77 | HTR2C (0.35) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2865912 | 0.77 | HTR2C (0.37) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2856594 | 0.70 | NPSR1 (0.47) | HTR2CHTR2AHTR2B | |
| SCHEMBL2859274 | 0.68 | HTR2C (0.40) | HTR2CHTR2AHTR2B | |
| SCHEMBL2858342 | 0.67 | SLC6A2 (0.44) | HTR2CHTR2AHTR2B | |
| SCHEMBL12062877 | 0.65 | HTR2C (0.44) | HTR2CHTR2AHTR2B | |
| SCHEMBL3661023 | 0.62 | — | — | |
| SCHEMBL9808049 | 0.62 | HTR2C (0.38) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2867919 | 0.62 | NPSR1 (0.46) | HTR2CHTR2AALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | HTR2C 264/4885HTR2A 685/4885ALDH1A1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.